TX-MAGNITUDE-SOFTWARE
20.4.2021 15:02:08 CEST | Business Wire | Press release
Magnitude Software, provider of continuous intelligence for the data-driven enterprise, today announced the release of Magnitude Angles Cloud, a cloud-based version of the company’s Angles process analytics solution. Angles Cloud greatly accelerates the delivery of powerful business insights from SAP and Oracle ERP systems directly to operational leaders in finance, supply chain, manufacturing and distribution, enabling them to make faster, more effective business decisions.
Traditional business intelligence reporting requires custom development by teams of data scientists, skilled in translating the complex data schema of ERP systems, to build reports consumable by business users. Magnitude Angles provides a context-rich business data model that abstracts this complexity and includes thousands of pre-configured templates and reports to put operational analytics in the hands of business users.
By eliminating the need for time-consuming custom development to provide near real-time business insights, business users can now make decisions quickly without having to rely on a data scientist to prepare and translate reports. The core Angles data model can also be connected to leading business intelligence (BI) tools, providing a “business brain” for these platforms that speeds report creation and effectiveness.
“It is often a challenge to easily get information out of SAP in a report format,” said Steve Hankins, CFO for Morgan Foods International, the largest private label soup manufacturer in the US. “Angles for SAP creates an abstraction layer for reporting that Morgan Foods has made extensive use of over the years and is embedded in the way we do things today. We’ve got a lot of business processes built around Angles. Because of that, we never considered implementing SAP S/4HANA without Angles. Our upgrade simply would not have been as successful without it.”
Angles Cloud combines the power of enterprise process analytics with the scale, performance and deployment speed of cloud. As a self-service, cloud-based solution, it can begin offering insights within a single day – far faster than any comparative on-premises process analytics platform.
“Angles Cloud is a significant milestone in allowing businesses to consume insights and increase an organization’s competitiveness,” said Jeffrey Shoreman, CEO for Magnitude. “Business insights are available at cloud speed, enabling customers to better anticipate supply chain disruptions, capture additional savings on their payment terms, and out-think and out-maneuver the competition.”
“We are excited to gain better insight into our supply chain, stock accounting and financial processes by adopting Magnitude Angles,” said Hans Platschorre, CFO for Hans Anders, a leading European optical retailer. “Angles Cloud will provide the value of self-service process analytics in a fast, secure and resilient cloud environment.”
Magnitude Angles empowers the data-driven enterprise to:
- Deliver deep insights and improved business outcomes through more than 2,000 industry-tailored, no-code business reports
- Transform ERP data into a source of continuous intelligence for real-time decision making across business functions
- Reduce the time-to-value of business analytics
- Improve BI projects with integrations to speed report development
Angles Cloud adds:
- Rapid deployment shortens time-to-insight to a single business day
- Cloud scale, elasticity and resilience
- Ability to deploy adjacent to cloud-based ERP landscapes and data warehouses for greater performance
To learn more or to request a demo, visit: https://www.magnitude.com/products/process-analytics
About Magnitude Software
Data is the fuel that powers the modern enterprise. Our mission is to help companies turn their core business data into continuous intelligence, providing actionable insights to shorten the path from data to decision. We enable our customers to connect data across enterprise applications and business processes including supply chain, finance and order management. Our relentless focus on innovation, customer experience and solving business problems is why more than 1,300 enterprises around the world trust Magnitude to put the power of their data into the hands of their business users. For more information visit magnitude.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005369/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom